ZimVie Inc.

Overview

• IndustryDental Equipment & Supplies²
• HeadquartersWestminster, United States²
• Incorporated inDE³
• Business address4555 Riverside Drive, Palm Beach Garden, Fl 33410³
• Filer categoryAccelerated filer³
• Legal formCorporation²
• LEI549300GFKURT1J6XR665²
• StatusActive²
• LEI statusIssued and current²
• Registered addressc/o The Corporation Trust Company, Corporation Trust Center 1209 Orange Street, 19803 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 6099735²

See how the biggest companies compare on our leaderboards

Corporate structure

ZimVie Inc. sits at the top of its group. 33 entities, 21 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ZimVie Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

We own or lease approximately 30 facilities around the world. Our corporate headquarters is in Palm Beach Gardens, Florida, which is also home to significant manufacturing operations and R&D activities.

We have two principal manufacturing site locations, described below, and a physical presence in approximately 20 countries.

Item 2 of the 10-K filed Feb 26, 2025.¹¹

Leadership

Who has led ZimVie Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerVafa Jamali Mar 10, 2022 to Mar 10, 2022¹²
• PresidentVafa Jamali Mar 10, 2022 to Mar 10, 2022¹²
• Chief financial officerRichard Heppenstall Oct 3, 2025 to now¹³

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

• 3DIEMME Srl Italy⁴
• Biomet 3i Australia Pty. Ltd. Australia⁴
• Biomet 3i Dental Iberica SLU Spain⁴
• Biomet 3i Mexico S.A. de C.V. Mexico⁴
• Biomet 3i Switzerland GmbH (Biomet 3i Schweiz GmbH) Switzerland⁴
• Biomet 3i UK Ltd. United Kingdom⁴
• Biomet 3i, LLC Florida⁴
• IC Guided Surgery, SRL Costa Rica⁴
• Implant Concierge, LLC Texas⁴
• JERDS Luxembourg Holding S.a.r.l Luxembourg⁴
• ZB Dental India Private Limited India⁴
• Zfx GmbH Germany⁴
• Zfx Innovation Srl Italy⁴
• ZimVie (Shanghai) Medical Device Co. Ltd. China⁴
• ZimVie Austria GmbH Austria⁴
• ZimVie Belgium N.V. Belgium⁴
• ZimVie Brasil Comercio, Importacao e Exportacao de Produtos Medicos Ltda. Brazil⁴
• ZimVie Chile Spa Chile⁴
• ZimVie France SAS France⁴
• ZimVie Germany GmbH Germany⁴
• ZimVie Holdings OUS LLC Delaware⁴
• ZimVie Holdings US 1 LLC Delaware⁴
• ZimVie Holdings US 2 LLC Delaware⁴
• ZimVie Japan G.K. Japan⁴

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

• ZB SpinCo Holdings, Inc.Aug 9, 2021 to Aug 9, 2021³

Timeline

1. Oct 20, 20258-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale²⁵
2. Oct 10, 20258-K Shareholder vote; Other events²⁶
3. Oct 3, 20258-K Other events²⁷
4. Jul 30, 20258-K Results of operations²⁸
5. Jul 21, 20258-K Entered a material agreement; Other events²⁹
6. May 13, 20258-K Shareholder vote³⁰
7. May 8, 20258-K Results of operations; Regulation FD disclosure³¹
8. Mar 13, 20258-K Executive or director change; Regulation FD disclosure³²
9. Feb 26, 20258-K Results of operations; Regulation FD disclosure³³
10. Oct 30, 20248-K Results of operations; Regulation FD disclosure³⁴
11. Aug 1, 20248-K Results of operations; Regulation FD disclosure³⁵
12. May 17, 20248-K Shareholder vote³⁶
13. Mar 10, 2022New chief executive Vafa Jamali becomes CEO¹²
14. Jul 30, 2021Founded ZimVie Inc. is founded²

Calendar

When it reported results

1. Jul 30, 2025Reported quarterly or annual results²⁸
2. May 8, 2025Reported quarterly or annual results³¹
3. Feb 26, 2025Reported quarterly or annual results³³
4. Oct 30, 2024Reported quarterly or annual results³⁴
5. Aug 1, 2024Reported quarterly or annual results³⁵
6. May 8, 2024Reported quarterly or annual results³⁷
7. Feb 28, 2024Reported quarterly or annual results³⁸
8. Nov 1, 2023Reported quarterly or annual results³⁹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

312 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 33 major events, 185 insider forms, 29 large holders, 50 other. The latest 20:

1. Nov 14, 2025SCHEDULE 13G/A EDGAR
2. Nov 13, 2025SCHEDULE 13G/A EDGAR
3. Oct 31, 202515-12G EDGAR
4. Oct 22, 2025SCHEDULE 13D/A EDGAR
5. Oct 20, 20254 EDGAR
6. Oct 20, 20254 EDGAR
7. Oct 20, 20254 EDGAR
8. Oct 20, 20254 EDGAR
9. Oct 20, 20254 EDGAR
10. Oct 20, 20254 EDGAR
11. Oct 20, 20254 EDGAR
12. Oct 20, 20254 EDGAR
13. Oct 20, 20254 EDGAR
14. Oct 20, 2025S-8 POS EDGAR
15. Oct 20, 2025S-8 POS EDGAR
16. Oct 20, 2025S-8 POS EDGAR
17. Oct 20, 20258-K EDGAR
18. Oct 10, 20258-K EDGAR
19. Oct 7, 2025DEFA14A EDGAR
20. Oct 3, 20254 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 7 buys and 2 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• J. Goldman & Co LPSCHEDULE 13G/A, 2 filings Feb 14, 2025 to Nov 14, 2025⁴⁰
• GLAZER CAPITAL, LLCSCHEDULE 13G/A, 2 filings Sep 10, 2025 to Nov 13, 2025⁴¹
• GAMCO InvestorsSCHEDULE 13D/A, 2 filings Jul 28, 2025 to Oct 22, 2025⁴²
• Camber Capital Management LPSCHEDULE 13G/A, 7 filings Mar 21, 2022 to Aug 27, 2025⁴³
• Divisadero Street Capital Management, LPSC 13G/A, 4 filings Jun 2, 2023 to Nov 14, 2024⁴⁴
• Eversept Partners, LPSC 13G, 1 filing Nov 14, 2024⁴⁵
• Neuberger BermanSC 13G/A, 2 filings Feb 12, 2024 to Oct 4, 2024⁴⁶
• INTEGRATED CORE STRATEGIES (US) LLCSC 13G, 3 filings Mar 21, 2023 to Jul 2, 2024⁴⁷
• Kent Lake Capital LLCSC 13G/A, 2 filings Apr 20, 2023 to Feb 14, 2024⁴⁸
• VANGUARD GROUP INCSC 13G/A, 2 filings Feb 9, 2023 to Feb 13, 2024⁴⁹
• BALYASNY ASSET MANAGEMENT L.P.SC 13G/A, 2 filings Jul 15, 2022 to Feb 14, 2023⁵⁰

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

SEC filer profile

How ZimVie Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARZimVie Inc.¹
• CIK0001876588
• Employer ID (EIN)87-2007795¹¹
• Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company¹¹
• Incorporated inDelaware¹¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)3843 Dental Equipment & Supplies¹
• SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance¹
• Business address4555 Riverside Drive, Palm Beach Garden, FL 33410¹
• Phone800-342-5454¹
• Shares outstanding28,200,941 as of Jul 25, 2025¹⁰
• Public float$493.7M as of Jun 28, 2024¹¹
• AuditorPricewaterhouseCoopers LLP, Miami, Florida PCAOB ID 238; it also attests to the company’s internal control over financial reporting¹¹
• On EDGAR sinceAug 9, 2021¹
• Filings325 in all: 4 (166), 8-K (32), 3 (14), SC 13G/A (14), SC 13G (13), 10-Q (11), DEFA14A (11), UPLOAD (8)¹
  All 33 form types

  CORRESP (6), SCHEDULE 13G/A (6), 4/A (5), 10-K (4), DRS/A (4), ARS (3), DEF 14A (3), S-8 (3), S-8 POS (3), DRSLTR (2), SCHEDULE 13G (2), SD (2), 10-12B (1), 10-12B/A (1), 15-12G (1), 25-NSE (1), 25-NSE/A (1), 8-K/A (1), CERT (1), DEFM14A (1), DRS (1), PREM14A (1), SCHEDULE 13D (1), SCHEDULE 13D/A (1), SEC STAFF ACTION (1)

• Latest filingsAnnual report (10-K) Feb 26, 2025
  Quarterly report (10-Q) Jul 30, 2025
  Proxy statement (DEF 14A) Mar 25, 2025
  Latest 8-K (8-K) Oct 20, 2025

Securities registered for trading

From the cover page of the 10-K filed Feb 26, 2025 (Section 12(b) of the Exchange Act).¹¹

Risk factors and legal proceedings

The risks ZimVie Inc. names in Item 1A of its 10-K filed Feb 26, 2025: 38 risks under these headings, as written.¹¹

• Risks Related to Our Business, Operations and Strategy
• Interruption of our manufacturing operations could adversely affect our business, financial condition and results of operations.
• Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by third-party suppliers could adversely affect our business, financial condition and results of operations.
• Our success depends on our ability to effectively develop and market our products against those of our competitors.
• Our restructuring and other cost reduction initiatives may not be successful or we may not fully realize the expected cost savings and/or operating efficiencies from our restructuring initiatives.
• To be commercially successful, we must effectively demonstrate to oral surgeons, dentists, DSOs and hospitals the value proposition of our products and procedural solutions compared to those of our competitors.
• If we fail to retain the employees and the independent agents and distributors upon whom we rely to market our products, customers may not buy our products and our results of operations may decline.
• If we do not introduce new products in a timely manner, our products may become obsolete over time, customers may not buy our products and our results of operations may decline.
• We are subject to cost containment measures in the U.S. and other countries, resulting in pricing pressures.
• Disruptions to our business from implementation of our new enterprise resource planning systems adversely impacted our operating results in 2022, and similar disruptions in 2025 or later years could have a material adverse impact on our business, results of operations, financial condition or cash flows.
• Our success largely depends on key personnel, including our senior management, and having adequate succession plans in place. We may not be able to attract, retain and develop the highly skilled employees we need to support our business, which could harm our business.
• We may be unable to achieve some or all of the strategic and financial benefits that we expect to achieve from the sale of our spine segment.

Legal proceedings

We are subject to various claims, legal proceedings and investigations regarding commercial, contractual, intellectual property, employment, product liability and other matters that arise in the normal course of business. We currently do not expect the outcome of these matters to have a material adverse impact on our results of operations, cash flows or financial position. However, the outcome of such matters is unpredictable, our assessment of them may change, and resolution of them could have a material adverse effect on our financial position, results of operations or cash flows.

For additional information related to our contingencies, see Note 16 to our consolidated financial statements included in Part II, Item 8 of this Annual Report, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.¹¹